NCT05699512

Brief Summary

Up to 20% of patients with Covid-19 develop symptoms that last more than 3 months, which is known as long Covid or Post-Covid-19 condition. The mechanism of the long term symptoms is not totally understood although inflammation, autoimmune reactions and thromboembolism are among suspected contributors. At Helsinki University hospital, a long Covid clinic was opened in June 2021. The aim of this cohort study is to monitor the patients that attend the clinic, follow up their functional abilities, quality of life and prognosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 15, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 24, 2022

Completed
1 year until next milestone

First Posted

Study publicly available on registry

January 26, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

January 26, 2023

Status Verified

January 1, 2023

Enrollment Period

2.5 years

First QC Date

January 24, 2022

Last Update Submit

January 25, 2023

Conditions

Keywords

Post Covid-19 conditionlong Covid

Outcome Measures

Primary Outcomes (1)

  • Change from baseline of WHODAS2.0 questionnaire as measured at 12 months

    Functional ability measured by WHODAS2.0 which is a measure developed by WHO and has 36 items. The minimum value is 0, the maximum value is 100. Higher score means worse functional ability.

    0, 3, 6, and 12 months

Secondary Outcomes (8)

  • EUROHIS-8 Quality of life

    0, 3, 6, and 12 months

  • Health related quality of life

    0, 3, 6, and 12 months

  • Depression

    0, 3, 6, and 12 months

  • Anxiety

    0, 3, 6, and 12 months

  • Symptom severity

    0, 3, 6, and 12 months

  • +3 more secondary outcomes

Interventions

Patients receive individual, tailored, multiprofessional rehabilitation

Eligibility Criteria

Age16 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with symptoms of long Covid that have lasted at least 3 mo after the primary infection

You may qualify if:

  • a diagnosed Covid-19 infection at least 3 mo before entry (either PCR positive or antigen test positive or hospitalisation because of Covid-19)

You may not qualify if:

  • patients for whom participation would be too exhausting, for example bed patients
  • patients who cannot fill in the questionnaires in Finnish

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Helsinki University Hospital

Helsinki, 00029, Finland

RECRUITING

Related Publications (1)

  • Virrantaus H, Liira H, Posharina T, Sulg A, Mantyla T, Kanerva M, Laakso S, Sainio M, Malmivaara A, Vuokko A, Varonen M, Venalainen M, Arokoski J. Prognosis of patients with long COVID symptoms: a protocol for a longitudinal cohort study at a primary care referred outpatient clinic in Helsinki, Finland. BMJ Open. 2023 Oct 17;13(10):e072935. doi: 10.1136/bmjopen-2023-072935.

Biospecimen

Retention: SAMPLES WITHOUT DNA

CRP, blood count, sedimentation rate, GT, krea, TSH, fasting glucose, ECG, Alat, Afos, K, Na, Ca, Alb, preAlb, B12-TC, cortisole

MeSH Terms

Conditions

Post-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

COVID-19Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Helena Liira, MD, PhD

    Helsinki University Central Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Helena Liira, MD, PhD

CONTACT

Jari Arokoski, Prof

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Physician

Study Record Dates

First Submitted

January 24, 2022

First Posted

January 26, 2023

Study Start

July 15, 2021

Primary Completion

December 31, 2023

Study Completion

December 31, 2024

Last Updated

January 26, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

We have applied for EU Horizon funding and potentially share data in that project.

Locations